Peptide Comparison
MGF vs PEG-MGF
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Two IGF-1 analogs in the same regimen: Moderate-High risk per peptide research literature. Multiple IGF-1 analogs compete for the same IGF-1R pool; the second analog does not raise peak receptor activation but stacks hypoglycemia exposure, cardiac/renal/hepatic hypertrophy signal, and peripheral neuropathy risk in heavy stacks.
Data-derived verdict
MGF and PEG-MGF share the igf-1 class and carry roughly equivalent evidence (Preclinical + Anecdotal / Anecdotal). On the catalogued data layer MGF has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; MGF's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| MGF | PEG-MGF | |
|---|---|---|
| Class | IGF-1 splice variant peptide; anabolic | Pegylated IGF-1 splice variant; anabolic |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Local muscle IGF-1 splice variant; activates satellite cells after mechanical damage | PEG conjugation extends half-life of MGF for systemic action |
| Route | IM (localized) | SC / IM |
| Half-life | ~5-7 min | ~2-3 days |
| Dosage (research) | 100-400 mcg post-workout IM into target muscle | 200-400 mcg SC 1-2x weekly |
| Evidence tier | Preclinical + Anecdotal | Anecdotal |
| Research depth | 68 indexed | 1 indexed |
| Availability | Research Chemical | Research Chemical |
| Reported risks | Very short half-life; injection site only; limited human data | Immunogenicity concerns with PEG; limited safety data |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick MGF or PEG-MGF?
MGF and PEG-MGF share the igf-1 class and carry roughly equivalent evidence (Preclinical + Anecdotal / Anecdotal). On the catalogued data layer MGF has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; MGF's evidence base is currently denser.
What is the difference between MGF and PEG-MGF?
MGF is classed as IGF-1 splice variant peptide; anabolic; PEG-MGF is classed as Pegylated IGF-1 splice variant; anabolic. Reported mechanism: MGF, Local muscle IGF-1 splice variant; activates satellite cells after mechanical damage; PEG-MGF, PEG conjugation extends half-life of MGF for systemic action. Reported half-life: MGF, ~5-7 min; PEG-MGF, ~2-3 days. Routes in published studies: MGF, IM (localized); PEG-MGF, SC / IM.
Which has stronger evidence, MGF or PEG-MGF?
PEG-MGF has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. MGF is graded Preclinical + Anecdotal, with 2 cited sources on its reference page and 68 indexed studies. PEG-MGF is graded Anecdotal, with 1 cited source on its reference page and 1 indexed studies.
Which is more accessible, MGF or PEG-MGF?
Neither MGF nor PEG-MGF is an FDA-approved drug. Catalog status: MGF, Research Chemical; PEG-MGF, Research Chemical. PEG-MGF's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.
Are MGF and PEG-MGF ever combined?
MGF and PEG-MGF appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two IGF-1 analogs in the same regimen, moderate-high risk.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…